Fosun Pharma Subsidiary Launches Co-Developed Biochemical Reagent with Siemens Healthineers
Shanghai Fosun Pharmaceutical (Group) Co., Ltd’s (SHA: 600196, HKG: 2196) subsidiary Fosun Diagnostics (Shanghai) Co.,...
HKG: 2196
Fosun Pharma Secures Licensing Deal for HCB101 SIRPα-Fc Fusion Protein
Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196, SHA: 600196) has entered into a licensing...
Fosun Pharma’s Serplulimab Approved for ES-SCLC in the UK and India
Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196, SHA: 600196) announced that its subsidiary Shanghai...
Fosun Pharma’s Fumaining Launches Clinically for Rare Disease Treatment in China
Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd.’s (HKG: 2196, SHA: 600196) in-house developed Category 1 drug...
Fosun Pharma Collaborates with Teva on Development of TEV-56278 in China and Southeast Asia
China’s Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) and Israel-based Teva Pharmaceutical...
Fosun Pharma’s Serplulimab Approved in Singapore and Malaysia for ES-SCLC Treatment
Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd. (HKG: 2196, SHA: 600196) announced that its subsidiary Shanghai...
Fosun Pharma’s FCN-159 and FCN-437c Win NMPA Marketing Approvals
Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced the receipt of marketing...
Fosun Pharma and Jiuyuan Gene Partner to Commercialize Biologics in Global Markets
Chinese pharmaceutical firms Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196; HKG: 2196) and Hangzhou...
Fosun Pharma’s HLX22 Granted Orphan Drug Designation by EU Commission
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that it has...
Fosun Pharma’s FCN-159 Granted Breakthrough Therapy Designation for Pediatric LCH
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its novel small-molecule...
Fosun Pharma’s LBP-ShC4 Receives FDA Approval for Androgenic Alopecia Study
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196, SHA: 600196) announced that it has...
Fosun Pharma Partners with Fakeeh Care Group to Advance Biopharmaceuticals in Saudi Arabia
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced a strategic partnership...
Fosun Pharma Reports Q1 2025 Revenues of RMB 9.42 Billion, Net Profits of RMB 765 Million
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) released its Q1 2025...
Fosun Pharma’s Henlius Strikes Deal with Sandoz for Global Rights to HLX13 Biosimilar
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its subsidiary...
Fosun Pharma’s 2024 Revenue Reaches RMB 41.1 Billion Amid R&D Investment
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has released its 2024...
Shanghai Fosun Pharmaceutical Transfers Unicorn II Holdings Stake to Warburg Pincus Subsidiary
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced plans to transfer...
Shanghai Fosun Pharmaceutical Gains NMPA Approval for XH-S003 in PNH Treatment
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced receiving clinical trial...
Fosun Pharmaceutical’s Foritinib Accepted for Review by China’s NMPA for NSCLC Treatment
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that the National...
Fosun Pharma’s 24-Valent Pneumococcal Vaccine Receives NMPA Approval for Phase I Trial
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd’s (SHA: 600196, HKG: 2196) subsidiary Fosun Adgenvax (Chengdu)...
Juvestar and Raziel Therapeutics Launch Phase III Study for RZL-012 in China
Juvestar Biotech Co., Ltd., a subsidiary of China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA:...